Pivotal Research Keeps a Buy Rating on Nu Skin (NUS)

By Ryan Adsit

Pivotal Research analyst Timothy Ramey reiterated a Buy rating on Nu Skin (NUSResearch Report) on March 8 and set a price target of $85. The company’s shares closed yesterday at $59.26, close to its 52-week low of $56.09.

According to TipRanks.com, Ramey is a 4-star analyst with an average return of 9.2% and a 58.0% success rate. Ramey covers the Consumer Goods sector, focusing on stocks such as Constellation Brands Inc, Post Holdings Inc, and Brown-Forman B.

Nu Skin has an analyst consensus of Moderate Buy, with a price target consensus of $78.67.

See today’s analyst top recommended stocks >>

Based on Nu Skin’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $17.76 million. In comparison, last year the company had a net profit of $18.24 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nu Skin Enterprises, Inc. engages in the development and distribution of beauty and wellness products and solutions. Its brands include Nu Skin and Pharmanex. The company was founded by Blake M. Roney, Sandra N. Tillotson, and Steven J. Lund in 1984 and is headquartered in Provo, UT.